APS Annual Meeting at Experimental Biology

The Protective Arm of the Renin-Angiotensin System

Symposium — Friday, April 30, 2021 — 2:00 PM - 3:30 PM — Virtual Session, Room APS-6
Cardiovascular Section — Chair: Rhian Touyz — Co-Chair: Thomas Unger

The “protective renin-angiotensin system” (RAS) involves the ACE2/angiotensin-(1-7)/Mas receptor and the AT2 receptor as a new opposing axis against the classical ACE/angiotensin II/AT1 receptor axis. Increased understanding of its signaling and regulation suggests that the RAS is more complex and relevant to human physiology and disease than thought until now. Despite the success of RAS blockade by ACE inhibitors and AT1R blockers, current therapies for hypertension and related cardiovascular diseases are still inadequate. Intensive research aimed at stimulating the AT2 receptor and upregulating the ACE2/angiotensin-(1-7)/Mas axis has led to the development of novel therapeutic approaches to counter-regulate the harmful effects of the ACE/angiotensin II/ AT1R axis.In this session we want to discuss new concepts related to molecular, pathophysiological, therapeutic and clinical aspects of the protective RAS. One important issue when examining Ang-(1-7) physiological and pathophysiological actions is to ensure that the GPCR MAS is indeed the protein of interest, which highlights the importance in discriminating between the different ‘Mas1’ proteins. An aspect of current intense research is the characterization of the cross-talk between the AT2-receptor and Mas due to its impact on receptor expression and trafficking, as well as on agonist binding and G-protein coupling. We want to describe and discuss several novel therapeutic approaches with the potential to provide improved cardiovascular protection and/or reduced adverse side effects which are already in preclinical and early clinical stages of development. Some of these new approaches have demonstrated benefits on stroke and obesity-associated vascular damage.


  • Introduction
    Rhian Touyz — Cardiovascular and Medical Sciences, University of Glasgow
    2:00 PM - 2:05 PM

  • AT2 Agonists As Treatment For Vascular Damage Associated To Obesity
    Marta Gil-Ortega — Ciencias Farmaceuticas y de la Salud., Universidad San Pablo CEU
    3:05 PM - 3:20 PM

  • Conclusion
    Thomas Unger — School for Cardiovascular Diseases, Maastricht University
    3:20 PM - 3:30 PM

Host Societies

Copyright © 2021 Experimental Biology (EB) | Experimental Biology® is a federally registered trademark of EB.